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Abstract 
Background: The metastases of a primary lung cancer over the thyroid gland are extremely rare. We report on an 
unusual presentation of thyroid metastasis of lung cancer in order to improve the management of similar cases.
Case presentation: Three years ago, a Moroccan male 59-year-old was admitted for dyspnea, dry cough, and chest 
pain. He had smoked about 30 cigarette packs a year. Clinical examination revealed a right thyroid nodule. Chest 
and neck computed tomography (CT) scan showed a proximal left tumor in contact with the pulmonary artery and 
revealed a suspected nodule in the right lobe of the thyroid with homolateral neck node. Transbronchial biopsy was 
performed and pathological examination revealed adenocarcinoma of the lung and positive for thyroid transcription 
factor. Other explorations carried out, such as brain CT, bone scan and abdominal ultrasound were normal. After a 
repeated negative fine needle aspiration biopsy of the suspected nodule of the right lobe of the thyroid, we per-
formed total thyroidectomy with neck dissection. An anatomopathologic exam revealed a tubulopapillary adenocar-
cinoma poorly differentiated. An Immunohistochemistry showed positive tumor cells with TTF1 and cytokeratin (CK) 
7 but negative cells with thyroglobulin and CK20. Thus, the pulmonary tumor was classified stage IV. Chemotherapy 
based on the combination of cisplatin and etoposide was conducted along with supportive care. The tumor grew 
up with brain metastases after three cycles of chemotherapy. Unfortunately, the patient died 2 months after despite 
brain radiotherapy.
Conclusion: We presented a medical case of a patient with thyroid metastasis resulting from a pulmonary adeno-
carcinoma which has rapidly evolved to brain metastases. The prognosis was pejorative in our clinical case (5 months 
after admission).
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Background
The metastases of a primary lung cancer to the thyroid 
gland are extremely rare [1]. The differential diagnosis 
with primary cancer of the thyroid is difficult because of 
the non-specific clinical symptoms and imaging [2, 3]. 
Malignant tumors of the thyroid can be subdivided into 
two groups: the primary tumors which have a slow evo-
lution, a usually locoregional extension and a good prog-
nosis. The histological types of these primary tumors are 
papillary carcinomas, follicular carcinomas, anaplastic 
carcinomas, medullary carcinomas and lymphoma. The 
second group consists of intrathyroid metastases. These 
metastases account for 2 to 4% of all clinical cases with 
thyroid malignant tumors [3, 4]. The prognosis is gen-
erally poor and depends on the histologic type of the 
primary tumor. The most commonly primary cancers 
implicated are kidney cancers, breast cancers, lung can-
cers, gastrointestinal cancers, followed by melanomas 
and lymphomas [5]. The proportion of these intrathyroid 
metastases reaches 24.2% in autopsy series, indicating 
that such metastatic involvements are much more com-
mon than has been clinically appreciated [3]. In these 
autopsy series, the breast and lung cancers are the pre-
dominant etiologies in North America [6] and digestive 
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cancers (esophagus and stomach) in Asia [7]. In these 
regions, pulmonary origin is, respectively, 13.6 [6] and 
25% [7] of the intrathyroid metastases. Other authors 
[2] noted that pulmonary origin represented 45.4% of 
intrathyroid metastases. There were five cases of thyroid 
metastases from pulmonary among 11 cases reported 
in all. The histological types of these lung cancers were 
squamous cell carcinomas (two cases), non-small cell 
lung cancer (two cases) and anaplastic small cell carci-
noma (1 case). The intrathyroid metastases from a lung 
adenocarcinoma is not commonly reported particularly 
in male patient. [2]. Only few cases of intrathyroid metas-
tases from primary lung adenocarcinoma were reported 
in literature [2]. In general, lung adenocarcinoma induces 
the distant metastases in the liver, adrenal, bone and 
brain. The intrathyroid metastases from pulmonary ori-
gin have been not yet reported in the Maghreb region. 
Recently, we experienced a case of lung adenocarcinoma 
with thyroid metastasis. The purpose of this report is to 
present this case and discuss the diagnostic difficulties of 
unexpected or unusual presentations of thyroid metasta-
sis of a lung adenocarcinoma.
Case presentation
Three years ago, a 59-year-old male Moroccan presented 
to the hospital with a dyspnea, dry cough, and a chest 
pain that had started 6  months before. He had smoked 
about 30 cigarette packs a year. He was diagnosed non-
insulin dependent diabetes 1 year before and was under 
oral anti-diabetics. He had undergone a successfully sur-
gical intervention for priapism 4 years before the current 
episode of sickness. His sister is known to have a breast 
adenocarcinoma. Physical examination at admission 
revealed a patient with performance status according to 
World Health Organization (WHO) quote one, and dysp-
nea type II according to NYHA (New York Heart Asso-
ciation). The pulmonary examination was poor. Head and 
neck examination found a right thyroid nodule without 
clinical signs of hypothyroidism or hyperthyroidism. 
Chest and neck computed tomography (CT) scan were 
performed and revealed a tumor in the left upper lobe of 
the lung, in contact with the pulmonary artery (Fig.  1a: 
chest axial cup CT-scan pulmonary window). The pul-
monary tumor measured 5.5  ×  6  cm without medi-
astinal lymph nodes (Fig.  1b: chest axial cup CT-scan 
mediastinal window). The neck CT-scan showed one 
nodule in the right lobe of the thyroid plunging into the 
superior mediastinum measuring 8 × 4 cm with homo-
lateral cervical lymph nodes (Fig. 2). The level of the thy-
roid stimulating hormone (TSH) was normal. For the 
pulmonary tumor, we performed transbronchial biop-
sies. Pathological examination of the biopsy revealed an 
adenocarcinoma of the lung, positive thyroid transcrip-
tion factor (TTF-1).
Other explorations conducted such as brain CT and 
bone scan and abdominal ultrasound were normal. We 
concluded a diagnosis of pulmonary adenocarcinoma 
classified T4N0M0 with a suspected nodule of the thy-
roid right lobe. We performed a repeated fine needle 
aspiration biopsy (FNAB) of the thyroid right lobe but the 
anatomopathologic results were negatives. We decided to 
performed a total thyroidectomy and lymph node dis-
section after extemporaneous anatomopathologic exam, 
confirming the malignancy of the thyroid right lobe nod-
ule. The pathologic examination revealed a moderately 
differentiated tubulopapillary adenocarcinoma (Fig.  3a, 
b) and three lymph nodes with extracapsular effraction. 
The immunohistochemistry showed positive tumor cells 
with TTF1 and cytokeratin (CK) 7 (Fig. 4a) but negative 
tumor cells with thyroglobulin and CK20 (Fig. 4b). Thus, 
the pulmonary tumor was classified stage IV (T4N0M1) 
Fig. 1 Computed tomography of the chest in pulmonary side (a) 
and mediastinal side (b). Helical chest CT scan. Axial cut after contrast 
injection. The pulmonary window (a) showed a heterogeneous tissue 
process developed at the expense of the posterior segment of the 
left upper lobe spiculated contours with lymphangitis around the 
tumor. This tumor measuring 5.5 × 6 cm. On mediastinal window 
(b): there were no pathologic mediastinal lymph nodes. Vascular axes 
were free and had normal caliber
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according to the 2009 UICC (Union for International 
Cancer Control) staging. The multidisciplinary team 
found that lung tumor was inoperable because it was 
in contact with the pulmonary artery. The decision to 
administrate chemotherapy followed by the chemoradia-
tion was retained because there was lack of places on the 
linear accelerator. A chemotherapy based on the com-
bination of cisplatin and etoposide was administrated 
along with supportive care. The chemotherapy con-
sisted of the combination of cisplatin and etoposide that 
were administered according to the following schema: 
for every cycle, cisplatin 75 mg/m2 on day 1 and etopo-
side 100 mg/m2 on day 1–3. The length of time between 
the treatments was 21  days. In total, two cycles of this 
chemotherapy were performed. We didn’t report any side 
effect regarding this chemotherapy. After the two cycles, 
the patient presented dizziness and headaches. A brain 
magnetic resonance imaging (MRI) was performed and 
showed multiples brain metastases. The cranial pallia-
tive radiotherapy 10 × 3 grays including five fractions per 
week was realized with best supportive care. This radia-
tion therapy was well tolerated. Particularly, there was no 
deleterious effect on cognition. After the radiation ther-
apy, we decided to go on with the chemotherapy admin-
istration. But the performance status of the patient was 
poor. Unfortunately, despite reanimation measures and 
best supportive care, the patient died 2 months later after 
brain radiotherapy.  
Discussion
Despite the complexity of the clinical symptomatology 
and our work context marked by our patients’ lack of 
financial means, we were able to make a single diagnosis. 
It is the result of systematic multidisciplinary approach 
of our working team. Unfortunately, the survival of our 
patient did not exceed 6 months despite the use of best 
therapeutic strategy. Brain metastases occurred earlier, 
2  months after the start of the chemotherapy. Did they 
go undetected in the initial brain scan? Metastasis of the 
thyroid are synchronous or metachronous of primary 
neoplasm, arising from 1  month to 26  years (median 
54 months) [4, 8]. In our case, the thyroid metastasis was 
synchronous. The clinical symptoms were not specific. 
In the majority of cases, the revelation mode is a unifo-
cal lesion of the thyroid, although multifocal or diffuse 
involvement is also seen [7]. The biological thyroid is 
Fig. 2 Cervical computed tomography scan—axial cup showing a 
large nodule in right lobe of thyroid, heterodense, dipping into the 
upper mediastinum and measuring 8 × 4 cm
Fig. 3 Pathological examination of the thyroid tumor showing a 
tubulo-papillary moderately differentiated adenocarcinoma (×200), 
b strong swelling
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usually in favor of euthyroidism and the thyroglobulin 
is normal. Rare cases of thyroid dysfunction have been 
reported; it was hypothyroidism due to metastatic infil-
tration and the replacement of the thyroid by cancer. In 
addition, it was hyperthyroidism due to follicular destruc-
tion by metastasis cells [9, 10]. The controversy about the 
place of surgery and the extent of surgical resection of 
intrathyroid metastases is widely reported in the litera-
ture [4]. The decision of conducting surgery of intra thy-
roid metastase is based on histological type of primary 
cancer, the location of intrathyroid secondary lesions, the 
kinetics of primary tumor and metastatic extension type 
(oligo or poly metastatic) [2]. Many authors [2, 3, 8, 10–
12] recommend the total thyroidectomy, especially when 
the rest of the workup proves negative. For those authors, 
the total thyroidectomy does not increase morbidity. It 
outweighs any secondary lesions intrathyroids multifo-
cal and avoids morbidity associated with locoregional 
evolution or local recurrence potential. In our case, there 
was no other distant metastases. Some authors [5] do not 
agree with the total thyroidectomy because the rest of the 
thyroid would continue to produce hormones that could 
have cytostatic properties. Those authors recommend the 
thyroidectomy when the primary tumor grows rapidly 
or when there are cervical symptom regarding tracheal 
compression The histologic type of our case (adenocar-
cinoma) and the tumor location in lung could explain the 
rapid evolution of the intrathyroid metastasis.
Other authors have analyzed the prognostic impact 
of thyroidectomy for intrathyroïd metastases [7] and 
concluded that thyroidectomy prevents subsequent 
metastasis dissemination and lengthens the interval 
between the diagnosis of metastasis and the death of 
patients but doesn’t affect the overall survival. The total 
thyroidectomy performed on our patient could be con-
sidered excessive. Nevertheless, the prolonged survival 
(7–22 years) reported in intrathyroïd metastase of renal 
cell carcinoma by many authors after thyroid resection 
(loboisthmectomie or total thyroidectomy) [2] could be 
in favor of our approach. The performance of a PetScan 
could help eliminate the involvement of the rest of the 
thyroid. We did not have this PetScan during the man-
agement of this case. Mean Survival rate is 2–60 months 
(mean 19  months) [13] for all thyroid metastasis and 
about 2 months for metastasis of a lung primary cancer 
of the thyroid gland [11, 14]. The poor survival of our 
case report could be explained by the lack of knowledge 
of the status as regards the epidermal growth factor 
receptor (EGFR) and anaplastic lymphoma kinase (ALK) 
mutations. Indeed, the identification of prospective 
molecular abnormalities can help to define the therapeu-
tic strategy. The search for these mutations is indicated 
in the following situations: non-small cell lung cancer 
including adenocarcinoma in advanced stage, female 
patient, no smoking or little smoking patient or Asian 
patient. Three mechanisms characterize these mutations 
in non-small cell lung cancers. An activating mutation of 
the genes of growth factor receptors (epidermal growth 
factor, human epidermal growth factor receptor-2) and 
intracellular transduction pathways: Kirsten rat sarcoma 
viral oncogene homolog (KRAS)/proto-oncogene B-Raf/
dual threonine and tyrosine recognition kinase (MEK) 
and phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit alpha (PIK3CA)/protein kinase AKT/
mammalian target of rapamycin (mTOR) pathway. These 
mutations stimulate tumor growth. Secondly, a transloca-
tion of the following genes: ALK, ROS proto-oncogene 1, 
receptor tyrosine kinase (ROS1) and The rearranged dur-
ing transfection (RET) proto-oncogene. These mutations 
induce a cascade of signals promoting cell proliferation, 
recruitment of new vessels and the ability of cells to move 
in blood circulation. Thirdly, the amplifications of genes 
Fig. 4 Immunohistochemistry of the thyroid tumor showing a 
diffusely positive cells for TTF1 and CK7 (×200), b negative cells for 
thyroglobulin and CK20 (×200)
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or overexpression of membrane proteins. In the EGFR 
and ALK mutations, targeted therapy inhibits the growth 
of tumor cells by blocking the activity of tyrosine kinase 
[15]. The EGFR and ALK status of our patient was not 
determined due to the absence of these tests in our struc-
ture and their high cost. In addition, targeted therapies in 
these mutations do not exist in our country presently and 
their costs are also unaffordable for our patients.
Conclusion
We presented a medical case of a patient with thyroid 
metastasis from pulmonary adenocarcinoma which has 
rapidly evolved into the development of brain metasta-
ses. The total thyroidectomy and chemotherapy did not 
appear to have any impact on the course of disease pro-
gression. Two months after the starting of chemotherapy, 
the brain metastases appeared earlier despite the perfor-
mance of a brain CT-scan in the initial workup. We rec-
ommend a brain MRI in the initial workup when there is 
suspected nodule of thyroid. The search of mutation of 
EGFR and ALK and administration of appropriate tar-
geted therapy could improve survival of patients with 
advanced lung adenocarcinoma. The prognosis was pejo-
rative in our clinical case (5 months after admission) and 
confirms the rapid progression to death, reported in the 
literature as regards lung adenocarcinoma with intrathy-
roid metastasis.
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